598744 Disclosed herein is a solid pharmaceutical compositions comprising 1% to 30% w/w (Z)-2- cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide (teriflunomide), 5% to 20 % w/w disintegrant, 0 % to 40 % w/w binder, 0.1 % to 2 % w/w lubricant, and the remaining percentage comprising diluents, provided that said solid pharmaceutical composition does not contain colloidal silicon dioxide. Additionally disclosed is a process for the preparation of the composition, and the use of the composition to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.
